Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07517510) titled 'HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL)' on April 1.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Guangdong Second Provincial General Hospital

Condition: Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)

Intervention: Drug: HVA

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: April 1, 2026

Target Sample Size: 40

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07517510

Published by HT ...